The FDA on September 30, 2022, granted accelerated approval to LYTGOBI® (Futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic Cholangiocarcinoma harboring Fibroblast Growth Factor Receptor 2 (FGFR2) gene fusions or other rearrangements. LYTGOBI® is a product of Taiho Oncology, Inc.
Bottom Ad
Advertisement
Subscribe
